simple and complex chemical substances have been made and tried in the treatment of the reticuloses and of malignant disease with variable and usually disappointing results; some of these have already been discussed recently at a meeting of this Section (Wilkinson, 1953) . Those substances of any value in the treatment of the reticuloses fall broadly into three main groups (Wilkinson, 1955) :
(a) Substances having specific nucleotoxic action-arresting mitosis, inhibiting cellular enzyme reactions and thus interfering with leucopoieses in the marrow, such as the 2chloralkylamines (nitrogen mustards), urethane, Myleran, colchicine and desacetylmethylcolchicine.
(b) Substances that act as metabolic antagonists to specific substances essential for cell growth and among these are folic acid antagonists (such as Aminopterin and amethopterin) and 6-mercaptopurine.
(c) The hormones-cortisone and adrenocorticotrophin. The ideal therapeutic agent for these diseases must be capable of correcting the marrow dyscrasias to permit of a return to normal blood cell formation, inhibition of abnormal pathological processes taking place in other tissues, such as lymph glands, spleen, skin, skeleton, without causing damage to normal tissues or producing other lesions such as aplastic anaemia, thrombocytopenic purpura, agranulocytosis, &c. Nitrogen Mustards (2-chloralkylamines) The first employed by me and still the most effective are tri-(2-chlorethyl)-amine and di-(2-chlorethyl)-methylamine given intravenously in the form of their very soluble hydrochlorides; the former is the most effective as the latter tends occasionally to cause some local venous thrombosis. Their local and general effects have been fully described previously but the most striking changes are those seen in the blood and marrow and their extremely rapid and effective ability to reduce in a few days even the most marked leucocytosis and gross glandular and splenic enlargement (see Wilkinson and Fletcher, 1947; Wilkinson, 1953) . This is particularly valuable where there is widespread involvement throughout the body and not localized to one group of glands. Hence, these substances are of the greatest value in the treatment of chronic leukaemias and especially generalized or widespread Hodgkin's disease. The white blood cells of the leuklemic patient as well as the normal person are very sensitive to the nitrogen mustards so that I rarely give a dose if the leucocyte count is below 15,000 per c.mm. On the other hand, in Hodgkin's disease and other similar reticuloses the leucocytes do not appear to be anything like so sensitive and therefore nitrogen mustards can be given to them with white blood cells as low as 4,000 c.mm. The nitrogen mustards are effective at any stage of the disease but it is desirable to use them without the complication of prior X-ray therapy which so frequently leads to marrow damage and the production of a severe refractory or aplastic anxmia.
The main therapeutic advantages of the 2-chloralkylamines are:
(1) With a correct technique they are very safe to use and then do not produce other hematological complications.
(2) Easy to control with proper dosage and adequate hkmatological supervision.
(3) Further courses can be repeated as required and usually have equally good effects.
(4) Longer intervals, between treatment, of symptomless improvement.
(5) They are easily given intravenously in out-patient clinics thus reducing very considerably the need for hospitalization and the time required for treatment-a considerable economic advantage as no special equipment is needed.
(6) They produce the most rapid relief of general systemic symptoms, and usually prompt reduction in the size of enlarged glands, liver, spleen, and often bone metastases.
(7) Marked leucocytosis in chronic myeloid and lymphatic leukimias is rapidly diminished to the level required.
(8) With the above improvements the patient rapidly gains weight and feels much better. (9) The effects may last for several months or years in some patients before a further course is required.
The disadvantages are:
(1) A good intravenous technique is essential.
(2) Nausea and occasionally severe vomiting may occur in 20 % and 2% of patients respectively.
(3) Inadequate heematological control or overdosage may cause aplasia, or leucopenia.
R.48 is one of a series of substances produced by Haddow and colleagues (1948) and can be given orally in doses of 50-800 mg. (most usually 100-300 mg.) daily. Although relatively non-toxic and mild it has proved disappointing in most cases but I have found it of value in some patients with Hodgkin's disease or chronic lymphatic leukemia having very poor veins unsuitable for intravenous therapy (Gardikas and Wilkinson, 1951; Wilkinson, 1953); Ramioul (1954) has also found it of value in Hodgkin's disease given orally or intramuscularly. Ulrethane (NH2.CO.OC2H5) Urethane in doses of 1-3 grams orally has a place in treatment although inferior to nitrogen mustards, but requires careful control, as it tends suddenly and without much prior warning to produce aplastic anemia or leucopenia (see Wilkinson, 1953) . Myleran (1 :4-dimethanesulphonyloxybutane) Myleran, described by Haddow and Timmis (1953) and Galton (1953) , has certainly proved of great value in treatment of chronic myeloid leukamia in doses of 1-4 mg. daily orless frequently, with adequatehaematological control. We found that in a group of 20 cases good results were obtained in 17 cases. Ultimately patients may fail to respond to this treatment or develop aplastic anamia or thrombocytopenia or severe anxemia necessitating discontinuance of treatment. Nevertheless, it has a valuable place in therapy.
6-Mercaptopurine
6-Mercaptopurine was introduced by Burchenal and others (1953) for the treatment of chronic myeloid leukaemia and acute leukemia but it had no value in chronic lymphocytic leulckmia, or Hodgkin's disease. In a way ithas notlived up to its expectations and in my experience it seems to have had the most beneficial effects in chronic myeloid leukimia in its acute myeloblastic phase especially in those becoming resistant to Myleran and other agents;
we have not had any striking results in acute leukaemia, but Burchenal says it may take 3 to 8 weeks to see any results if the patient has minimal haemorrhagic manifestations and is likely to survive that necessary period for treatment.
Desacetyl-methylcolchicine
Following the observations that colchicine could have an effect on leukemic processes in spite of its toxicity a substituted derivative desacetyl-methylcolchicine (Colcemid) has been prepared and a few cases were reported by Moeschlin and others (1954) . In a group of cases that Leonard and I have investigated, there is no doubt it is of value in the treatment of chronic myeloid leukimia. It is of no value in chronic lymphatic leukwmia and proved of little use in acute leukemia. It certainly provides a rapid fall in the white cell count, and marked reduction in the size of the spleen without impairing the red cell and platelet counts (Leonard and Wilkinson, 1955) . Triethylene melamine (2.4.6.-triethyleneimino-s-triazine; T.E.M.) This is a powerful and quite toxic substance that has been used parenterally in doses of 0-15-018 mg./kg. bodyweight but its effects are somewhat unpredictable since individual tolerance varies so much and marrow aplasia or leucopenia can readily occur in a high proportion of cases as has been noted by most users of it. Its activity seems to be associated with its ethyleneimino groups-which resemble the ethyleneimonium transformations that occur with the nitrogen mustards (Wilkinson, 1955) . 366 8 Many other substances have been tried such as TEPA (NN'N"triethylenephosphoramide), DEPA (NN'diethylene phosphoramide) and more recently THIOTEPA (triethylenethiophosphoramide) which can be given intramuscularly, with variable but encouraging results.
Folic Acid Antagonists
The only ones of particular interest and value in this group have been Aminopterin (4-aminopteroylglutamic acid) and amethopterin (4-amino-N'0-methylpteroylglutamic acid).
They have been used most effectively both orally and parenterally in the treatment of acute leukemias (Farber et al., 1948; Farber, 1949) and reticuloses, and my own results have been described fully elsewhere (Wilkinson, 1948 (Wilkinson, , 1953 Wilkinson and Gardikas, 1951) .
They appear to act as antimetabolites which, in the specific enzyme system concerned, prevent folic acid from stimulating abnormal leucocyte formation in the marrow: The most effective results have been noted in children with acute leuklmias.
Cortisone and ACTH
The mode of action of these hormones in the treatment of the leuklmias and reticuloses is unknown-nevertheless, they play an important, though temporary, role in the successful relief for a time of acute leuklmias, especially in children. According to different authors 30-90% of children with acute leukemia show remissions that may last for up to twelve months. Subsequent treatment after relapses is not so effective. Nevertheless, a smaller group of patients do get longer and complete remission-my longest case, a girl of 7 years, has now survived three and three-quarter years, is clinically normal and has still got a completely normal blood count and bone-marrow. These hormones are quite definitely the best treatment for acute leuklmias at the present time but have little or no value at all with the other reticuloses.
Results
In discussing the treatment of the various reticuloses with chemotherapeutic agents I shall consider them in the light of the results in my own series of over 700 patients treated since 1942, although the majority of necessity date from 1946.
Since it is quite well known that many mild cases of Hodgkin's disease and chronic lymphatic leukzemia, especially in older patients, are quite benign and often do not require treatment over many years, if at all, all my treated patients in this series were moderately severe or very severe cases, some having failed to respond adequately to previous radiotherapy. The mild types of cases were not treated at all unless they later developed more severe conditions necessitating this. Hodgkin's disease (Tables I, II obtained with R.48 in 20 patients with total dosages of 2-95 grams; of these 30% (6 cases) were completely relieved in three to twenty-one weeks, 4 being still alive after two and a half, three, three, and five and a half years respectively; 1 died of auricular fibrillation (two years) and 1 of cerebral hemorrhage ten months later. Urethane (6 cases), cortisone (7 cases) and ACTH (6 cases) had no beneficial effects.
Of 58 severe patients treated for at least twelve months prior to January 1953 the survivals are shown in Fig. 1 .
Of other reticuloses only intravenous tri-(2chlorethyl)-amine hydrochloride given to 20 patients (12-40 mg.) produced any beneficial results up to two years as will be seen by referring to Table II . 
Chronic Leukemias
As already mentioned above, the mild elderly patient with chronic lymphatic leukxmia usually requires little or no treatment (see Wilkinson, 1953 Wilkinson, , 1955 .
The most rapid and effective therapy is by intravenous nitrogen mustard which will reduce the high leucocyte count in the course of a few days, cause rapid reduction in size of spleen, liver and glands, and is undoubtedly the quickest method of relieving mechanical pressure symptoms due to enlarged organs and glands.
Of 126 patients with chronic myeloid and lymphatic leukaemias there were 70 myeloid cases with splenomegaly who showed complete regression in 46% and partial improvement in a further 48 %, while 31 % of the lymphatic cases likewise showed complete regression and a further 60 % partial reduction in size of the spleen. These reductions in the splenomegaly were accompanied by complete clinical improvement and only 5-7 and 90% of the myeloid and lymphatic patients respectively showed no improvement.
Similar profound improvements were noted in fatigability, anorexia, fever, sweating and loss of weight (see Table I , Wilkinson, 1953) .
In these patients with chronic leukaemia the duration of remissions between separate courses of treatment comprising 1-4 injections of 5-6 mg. each were 2 patients for more than two years, 11 (thirteen to twenty-four weeks), 14 (seven to twelve months), 31 (four to six months), and 59 (one to three months), i.e. 21 and 46% of patients did not require further treatment for at least three and six months respectively.
In a comparison with other similar series receiving treatment by irradiation the survival figures from commencement of treatment compare very well indeed as will be seen in Table III.   TABLE III The value of 6-mercaptopurine in the treatment of chronic myeloid leukeemia is still under investigation but it seems to be quite hopeful: splenomegaly rapidly diminishes, the high white cell count is reduced quite promptly, but less rapidly than with the nitrogen mustards, while the hemoglobin and red cell count increase. Thus in one patient who received 200 mg. daily for eighteen days and then continued on a maintenance dose of 50 mg.
the white cell count was reduced from 272,000 to 31,000, the hlmoglobin rose from-54% to 94%, the spleen became impalpable and she was well seven months later.
A new series of 7 previously untreated patients with chronic myeloid leukiemia were given desacetyl-methylcolchicine (Colcemid) (initially 5-10 mg. and maintenance 2-5 mg.
daily) orally with most encouraging results (Table IV) , and it will be noticed that the spleno- megaly was markedly reduced in 5 patients and partially in 1 other, only 1 failing to improve in this respect, although all of them showed marked lowering of the high white cell count and an increase in the red cell count and hemoglobin with great improvement in their general clinical conditions. Acute Leukaemias It has been well established now that almost without exception any form of treatment effective for chronic leukeemia (whether chemotherapy or radiotherapy) is quite ineffective for the relief of acute leukeemias. However, I have demonstrated (Table I in Gardikas and Wilkinson, 1952; Wilkinson, 1953) that when the white cell count is much increased, as may occur at times in acute leukemia, one intravenous injection of 6 mg. of tri-(2-chlorethyl)-amine hydrochloride may be quite adequate to reduce the count to normal levels, thus permitting the appropriate therapy to be instituted for the acute phase.
A series of 43 patients with acute leukemia were given Aminopterin by Wilkinson (1948, 1953) and Wilkinson and who found that 10 patients (23%) (5 myeloblastic, 3 lymphatic and 2 monocytic leukemia) had complete (2) or partial (8) remissions (see Table  VII , Wilkinson, 1953) .
After treatment with cortisone or ACTH given to a group of 76-patients with acute leukaemias of different types, 52 failed to show any clinical orhaematological responses. Of the remainder, 17 (7 myeloblastic and 10 lymphatic) had partial remissions while 7 (4 myeloblastic and 3 lymphatic) responded completely, i.e. there was clinical and haematological improvement in 31 % (24 cases) of the whole series (see Tables IX and X, Wilkinson, 1953;  TablesV1II, IX, X, Wilkinson, 1955) . As mentioned above, the longest surviving patient with acute lymphatic leukaemia in this group, and one of the first to be treated, is still alive after three and three-quarter years with a normal blood count, bone-marrQw and clinical condition. Other patients have survived for lesser periods of twelve to twenty-four months.
Myelomatosis
The treatment of this condition has always been disappointing, the most helpful agents having been urethane, nitrogen mustards, ACTH (cortisone) and the various substituted stilbamidines. In my experience by far the best results have been obtained by the use of urethane in doses of 1-3 grams daily orally, and my results are summarized in Table V showing that in 19 patients there was slowing of the disease process, prolongation of life, relief of pain and, quite often, temporary healing of the bone lesions.
Summary
The chemotherapeutic treatment of the reticuloses is usually an easily controlled, economical and efficient method of dealing with them, particularly where the condition is generalized, severe or in an acute phase; these chemical agents offer the quickest and most effective therapy in these patients and also when there are severe mechanical pressure symptoms or extreme leucocytosis.
For Hodgkin's disease the best and most effective therapy is with tri-(2-chlorethyl)-amine hydrochloride (Trillekamin) intravenously, but in some patients T.E.M. or even R.48 may be of value.
For the other reticuloses such as Brill-Symmers syndrome, follicular lvmphoblastoma, myeloid reticulosis, acute reticulosis and reticulum cell reticulosis, the nitrogen mustards and sometimes splenectomy seem to be the best therapy for a very difficult group of conditions. For the leukemias there is no doubt that the intravenous nitrogen mustards give the most prompt, effective and long-standing results with both chronic myeloid and chronic lymphatic forms; combined or prior radiotherapy is very undesirable. Good results are also obtained in myeloid leukxemias using Myleran, desacetyl-methylcolchicine (Colcemid), 6-mercaptopurine and urethane orally. In some cases of chronic lymphatic leukxmia, T.E.M. and R.48 orally, or THIOTEPA intramuscularly, have also been of great value.
The acute leuklmias of all types have shown the best results after treatment with Aminopterin (or amethopterin), or cortisone orally, or ACTHI intramuscularly or intravenously.
USrethane is undoubtedly the best treatment for myelomatosis.
